Advertisement

Neurogenetics pp 131-141 | Cite as

Multiplexed Fluorescence Analysis for Mutations Causing Tay-Sachs Disease

  • Tracy L. Stockley
  • Peter N. Ray
Part of the Methods in Molecular Biology™ book series (MIMB, volume 217)

Abstract

Tay-Sachs disease is a severe, neurodegenerative disease fatal in childhood that is caused by deficiency of the enzyme β-hexosaminidase A (Hex A) (1). Tay-Sachs is most common in the Ashkenazi Jewish population, with an incidence of 1/3600 affected individuals and a carrier rate of approx 1 in 30 (1). Owing to the severity of the disease and the high incidence, carrier screening for Tay-Sachs disease has been available to Ashkenazi Jewish individuals since the 1970s, which has greatly reduced the number of affected children in this population. The standard method of carrier testing is by biochemical analysis for reduced Hex A activity in serum (2).

Keywords

Mutant Allele Carrier Screening Carrier Testing Ashkenazi Jewish Population Resultant Polymerase Chain Reaction Product 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Gravel, R. A., Clarke, J. T. R., and Kaback, M. M. (1995) The GM2 gangliosidoses, in The Metabolic and Molecular Bases of Inherited Disease (Scriver, C.R., Beaudet, A.L., Sly, W.S., and Valle, D., eds.), McGraw-Hill, New York, USA, pp. 2839–2879.Google Scholar
  2. 2.
    O’Brien, J. S., Okada, S., Chen A., and Fellerup, D. L. (1970) Tay-Sachs disease. Detection of heterozygotes and homozygotes by serum hexosaminidase assay. N. Engl. J. Med. 283, 15–20.PubMedCrossRefGoogle Scholar
  3. 3.
    Natowicz M. R. and Prence, E. M. (1996) Heterozygote screening for Tay-Sachs disease: past successes and future challenges. Curr. Opin. Ped. 8, 625–629.CrossRefGoogle Scholar
  4. 4.
    Triggs-Raine B. L., Mules, E. H. Kaback, M. M., Lim-Steele, J. S. T., Dowling, C. E., Akerman, B. R., et al. (1992) A pseudodeficiency allele common in non-Jewish Tay-Sachs carriers: Implications for carrier screening. Am. J. Hum. Genet. 51, 793–801.PubMedGoogle Scholar
  5. 5.
    Cao, Z., Natowicz, M. R., Kaback, M. M., Lim-Steele, J. S. T., Prence, E. M., Borwn, D., et al. (1993) A second mutation associated with apparent β-hexosaminidase A pseudo-deficiency: identification and frequency estimation. Am. J. Hum. Genet. 53, 1198–1205.PubMedGoogle Scholar
  6. 6.
    Myerowitz, R. and Costigan, F. C. (1988) The major defect in Ashkenazi Jews with Tay-Sachs disease is an insertion in the gene for the α-chain of β-hexosaminidase. J. Biol. Chem. 263, 18,587–18,589.PubMedGoogle Scholar
  7. 7.
    Myerowitz, R. (1988) Splice junction mutation in some Ashkenazi Jews with Tay-Sachs disease: evidence against a single defect within this ethnic group. Proc. Natl. Acad. Sci. USA 85, 3955–3959.PubMedCrossRefGoogle Scholar
  8. 8.
    Arpaia, E., Dumbrille-Ross, A., Maler T., Neote, K., Tropak, M., Troxel, D., et al. (1988) Identification of an altered splice site in Ashkenazic Tay-Sachs disease. Nature 333, 85–86.PubMedCrossRefGoogle Scholar
  9. 9.
    Navon, R. and Proia, R. L. (1989) The mutations in Ashkenazi Jews with adult GM2 gangliosidosis, the adult form of Tay-Sachs disease. Science 243, 1471–1474.PubMedCrossRefGoogle Scholar
  10. 10.
    Paw, B. H., Kaback, M. M., and Neufeld, E. F. (1989) Molecular basis of adult-onset GM2 gangliosidoses in patients of Ashkenazi Jewish origin: Substitution of serine for glycine at position 269 of the α-subunit of β-hexosaminidase. Proc. Natl. Acad. Sci. USA 86, 2413–2417.PubMedCrossRefGoogle Scholar
  11. 11.
    Triggs-Raine, B. L., Feigenbaum, A. S. J., Natowicz, M., Skomorowski, M. A., Schuster, S. M., Clarke, J. T. R., et al. Screening for carriers of Tay-Sachs disease among Ashkenazi Jews: a comparison of DNA-based and enzyme-based tests. N. Engl. J. Med. 323, 6–12.Google Scholar
  12. 12.
    Wu, D. Y., Ugozzoli, L., Pal, B. K., and Wallace, R. B. (1989) Allele-specific enzymatic amplification of beta-globin genomic DNA for diagnosis of sickle cell anemia. Proc. Natl. Acad. Sci. USA 86, 2757–2760.PubMedCrossRefGoogle Scholar
  13. 13.
    Howard, T. D., Bleecker, E. R., and Stine, O. C. (1999) Fluorescent allele-specific PCR (FAS-PCR) improves the reliability of single nucleotide polymorphism screening. BioTechniques 26, 380–381.PubMedGoogle Scholar
  14. 14.
    Walsh, P. S., Metzger, D. A., and Higuchi, R. (1991) Chelex 100 as medium for simple extraction of DNA for PCR-based typing from forensic material. Biotechniques 10, 506–513.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2003

Authors and Affiliations

  • Tracy L. Stockley
    • 1
  • Peter N. Ray
    • 1
  1. 1.Division of Molecular GeneticsHospital for Sick ChildrenTorontoCanada

Personalised recommendations